A Phase 1 Trial to Evaluate Safety and Pharmacokinetics of ABBV-243 in Healthy Adults
Phase 1
66
about 1.5 years
18–60
1 site in IL
What this study is about
Researchers are testing the safety, tolerability, pharmacokinetics, and immunogenicity of a treatment called ABBV-243. Participants will receive either an intravenous (IV) dose or a subcutaneous (SC) dose of ABBV-243, or a placebo. The trial will last for 532 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ABBV-243
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Maximum Observed Serum Concentration (Cmax) of ABBV-243, Number of Participants with Adverse Events (AEs), Terminal Phase Elimination Half-Life (t1/2) of ABBV-243, Time to Cmax (Tmax) of ABBV-243